摘要
目的检测非小细胞肺癌患者的血清蛋白质谱,探讨非小细胞肺癌血清蛋白质指纹图与临床分期的关系,为非小细胞肺癌预后判断、临床治疗决策选择提供依据。方法共收集69例非小细胞肺癌患者血清,应用阳离子交换蛋白(CM10)芯片,通过表面增强激光解吸电离-飞行时间-质谱(SELDI-TOF-MS)技术检测非小细胞肺癌患者血清蛋白质质谱,应用生物信息学方法分析血清蛋白质指纹图与非小细胞肺癌临床分期的关系。结果比较28例Ⅰ～Ⅱ期与41例Ⅲ～Ⅳ期非小细胞肺癌蛋白指纹图,共筛选出68个有显著性差异的质荷比峰(m/z),最终筛选出2个潜在标志物5 632 m/z、13 779 m/z。5 632 m/z、13 779 m/z均在Ⅲ～Ⅳ期非小细胞肺癌中高表达,在Ⅰ～Ⅱ期非小细胞肺癌中低表达。将此标记物作为非小细胞肺癌分期模型,其正确指数为0.587,一致率为79.5%,Kappa=0.32。结论 SELDI-TOF-MS技术检测非小细胞肺癌患者血清蛋白质质谱,筛选出m/z位于5 632、13 779的蛋白质峰可能是非小细胞肺癌术前临床分期的标记物。
Objective To detect proteomic changes in non-small cell lung cancer and find the association of serum protein profiles with the clinical stage.Methods Twenty-eight cases of stage Ⅰ-Ⅱ non-small cell lung cancer and 41 cases of stage Ⅲ-Ⅳ were detected.Protein fingerprints were detected by surface-enhanced laser desorption/ionization-time of flight-mass spectrometry（SELDI-TOF-MS） and a CM10 chip.Bioinformatics was used to analyze the relationship between the serum proteomic fingerprint and clinical staging in non-small cell lung cancer.Results Comparing proteomic changes between stage Ⅰ-Ⅱ and stage Ⅲ-Ⅳ groups,68 discrepant proteins were selected.The best combination consisted of 5 632 m/z and 13 779 m/z,which were highly expressed in stage Ⅲ-Ⅳ non-small cell lung cancer and lowly expressed in stage Ⅰ-Ⅱ,with an accuracy of 0.587 and a compatibility of 79.5%,Kappa=0.32.Conclusions SELDI-TOF-MS can be used to detect serum protein profiles in non-small cell lung cancer,and selected 5 632 m/z and 13 779 m/z might be markers for clinical staging before operation.
出处
《山东大学学报（医学版）》
CAS
北大核心
2011年第9期132-135,共4页
Journal of Shandong University:Health Sciences
基金
山东省科技发展计划项目(2007GG20002007)
山东省优秀中青年科学家科研奖励基金(博士基金BS2009SW050)
山东省医药卫生科技发展计划资助课题(2009HZ063)
关键词
肺肿瘤
生物信息学
临床诊断
蛋白质质谱
Lung carcinoma
Medical informatics
Clinical diagnosis
Proteomic profile
